Business Wire Nigeria
Worldwide Network Monitoring Market to 2026 - Featuring Garland Technology, Apcon & Big Switch Networks Among Others - ResearchAndMarkets.com - Business Wire
DUBLIN--(BUSINESS WIRE)--The "Network Monitoring Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2026" report has been added to ResearchAndMarkets.com's offering. The report on the global network monitoring market provides qualitative and quantitative analysis for the period from 2018 to 2026. The report predicts the global network monitoring market to grow with a CAGR of 9.4% over the forecast period from 2020-2026. The study on network monitoring market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2018 to 2026. The report on network monitoring market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global network monitoring market over the period of 2018 to 2026. Moreover, the report is a collective presentation of primary and secondary research findings. Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global network monitoring market over the period of 2018 to 2026. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider. What does this report deliver?
- Comprehensive analysis of the global as well as regional markets of the network monitoring market.
- Complete coverage of all the segments in the network monitoring market to analyze the trends, developments in the global market and forecast of market size up to 2026.
- Comprehensive analysis of the companies operating in the global network monitoring market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
- Rapid industrialization and growing adoption of IoT based technology and BYOD devices by organizations
- Rise in complex networking, security concerns and increasing demand for continuous monitoring
- High cost involve in installation
- Increasing demand of network monitoring from small and medium scale industries
- Cisco Systems, Inc.
- Garland Technology, LLC
- Apcon, Inc.
- Big Switch Networks, Inc.
- IBM Corporation
- Accedian Networks, Inc.
- AppNeta, Inc.
- Juniper Networks, Inc.
- NETSCOUT Systems, Inc.
Vizient Data Show 610% Increase in Demand for Dexamethasone after Study Shows Effectiveness for Patients Severely Ill with COVID-19 - Business Wire
Vizient shares data showing a 610% increase in demand by its members for dexamethasone in the week since study linking treatment for COVID patients.
IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. today shared data showing a 610% increase in demand by its member hospitals for dexamethasone, a commonly used corticosteroid, in the week since the initial trial results of a clinical study* conducted in the United Kingdom showed it reduced the mortality of patients who are severely ill with COVID-19. As a result of the spike in demand, fill rates for the products are now at 54% for Vizient member hospitals. With the number of COVID cases continuing to persist across the U.S., news of a drug that has initially been shown to be effective for treating patients requiring oxygen or a ventilator is quickly adopted by clinicians who are treating the most severe patients. We looked at data on the day of the announcement of the trials results and saw that aggregated demand for dexamethasone vials and tablets had spiked 183% said Dan Kistner, PharmD, group senior vice president, pharmacy solutions for Vizient. Now, six days later, aggregated demand is up 610% and the fill rate has dropped from 97% to 54%. Dexamethasone has been used since the 1960s to reduce inflammation in a range of conditions, including inflammatory disorders and certain cancers. It is categorized as a high impact drug in Vizients essential medicines list. Drugs in this category have alternatives available, but they may be less clinically desirable and/or are more operationally difficult to use, or where their absence can affect therapeutically-related drugs. While demand is surging, Kistner is cautiously optimistic that manufacturers and distributors will be able to adjust quickly to increase the availability of the drug and appropriately manage allocations as necessary. However, as the spike in demand illustrates, it is critically important for manufacturers to begin building additional resiliency into pharmaceutical inventory capacity given the potential for rapidly changing demand. Dexamethasone is a workhorse drug for hospitals and it is good that there are several manufacturers in the supply chain. Vizient is in communications with both manufacturers and distributors about the increase in demand and will be monitoring availability and supply of various presentations of dexamethasone as we continue to see the increase in demand,said Kistner. *This study is awaiting peer review at this time. About Vizient, Inc. Vizient, Inc. provides solutions and services that improve the delivery of high-value care by aligning cost, quality and market performance for more than 50% of the nations acute care providers, which includes 95% of the nations academic medical centers, and more than 20% of ambulatory providers. Vizient provides expertise, analytics and advisory services, as well as a contract portfolio that represents more than $100 billion in annual purchasing volume, to improve patient outcomes and lower costs. Vizient has earned a Worlds Most Ethical Company designation from the Ethisphere Institute every year since its inception. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.